Related Experiment Video
Updated: Apr 28, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Oncolytic viruses for potential osteosarcoma therapy
Pooja Hingorani1, Valerie Sampson, Christina Lettieri
1Center for Cancer and Blood Disorders, Phoenix Children's Hospital, 1919 E Thomas Road, Phoenix, AZ, 85016, USA, phingorani@phoenixchildrens.com.
Abstract:
Since the first anecdotal reports of dramatic tumor responses following a viral infection in early 1900s, the field of oncolytic virotherapy has evolved at a rapid pace finally making its way into clinical trials. A large number of both wild-type and genetically altered viruses with a preferential replication-competency for tumor cells have been studied in tissue cultures, animal models and in humans, with an ever increasing repertoire of new viruses being added to this pool. Although oncolytic viruses have caused dramatic antitumor responses in cell cultures and mouse models, their clinical effects in humans have been modest. Therefore, the current research is focused on understanding the mechanisms by which viruses kill tumor cells, the barriers to successful viral delivery and penetration into tumor cells, the role of the immune system in viral oncolysis and generating stronger target specific and replication competent viruses. Osteosarcoma is a challenging malignancy to identify novel targets for therapy due to its complex genetic make-up. Oncolytic virotherapy may be a promising approach as a novel therapeutic, not dependent on consistent expression of a single target. In this review we summarize the supportive evidence and rationale for use of viral oncolysis in osteosarcoma along with the specific challenges it may face.
Insights
Oncolytic virotherapy uses viruses to target and destroy cancer cells. While promising, its clinical success in humans, particularly for osteosarcoma, remains modest, necessitating further research into viral mechanisms and delivery.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Oncolytic virotherapy has progressed from early observations to clinical trials, utilizing viruses that selectively replicate in tumor cells.
- Despite significant preclinical success, oncolytic viruses have shown limited clinical efficacy in humans.
- Current research aims to overcome barriers in viral delivery, tumor cell penetration, and immune system interactions to enhance oncolytic virus effectiveness.
Purpose of the Study:
- To review the evidence and rationale supporting the use of oncolytic virotherapy for osteosarcoma.
- To identify and discuss the specific challenges associated with applying oncolytic virotherapy to osteosarcoma treatment.
Main Methods:
- Review of existing literature on oncolytic virotherapy.
- Analysis of preclinical and clinical data regarding viral oncolysis.
- Examination of the genetic complexity of osteosarcoma and its implications for targeted therapies.
Main Results:
- Oncolytic viruses demonstrate potent antitumor effects in cell cultures and animal models.
- Clinical responses to oncolytic virotherapy in humans have been modest.
- Osteosarcoma presents unique challenges for targeted therapies due to its complex genetic profile.
Conclusions:
- Oncolytic virotherapy offers a potential therapeutic strategy for osteosarcoma, independent of specific molecular targets.
- Further research is crucial to optimize viral agents, improve delivery, and enhance immune responses for effective clinical translation in osteosarcoma.
More Related Videos
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...